Sat, Jul 12, 2014, 11:11 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Allergan Inc. Message Board

gmger21 4 posts  |  Last Activity: Feb 3, 2014 1:01 PM Member since: Apr 5, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Even if approved stock may go down

    by peterpelican Feb 3, 2014 12:18 PM
    gmger21 gmger21 Feb 3, 2014 1:01 PM Flag

    Even If approve stock may go up!!! LOL moron

  • Reply to

    Dumped all ... Pink Sheet co.

    by peterpelican Feb 3, 2014 12:09 PM
    gmger21 gmger21 Feb 3, 2014 12:58 PM Flag

    yeah your right Par Pharma partner with IGXT and realize it was a pink sheet co. LOL moron LOL

  • Here is a Summary from he largest Shareholder of IGXT (he sees Tgt of $5-10) !!! PART 1
    Blumont currently hold over 6 Million shares of IGXT ...
    ----

    Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the
    life of the BIPES Fund has never seemed more reason able—the company has put in place more
    than enough building blocks to see that kind of sto ck price by the of 2016, as it becomes
    recognized as a world leader in the growing area of thin-film drug delivery and development. I
    like the fact that my $3 low end corresponds to the already-existing 1-year target of Ram
    Selvaraju, a well-respected and sophisticated Wall Street biotech analyst. If the PAR
    partnership blossoms into something special (whichis what I expect), the $5-$10 range becomes a real possibility.

    1) IntelGenx has a branded drug (ForFivo) which they s
    uccessfully negotiated through to
    FDA approval. Although ForFivo is not a “big” drug
    , royalties and milestones from this
    drug should end up covering IntelGenx’s $2million/y
    ear operating burn; the industry
    credibility that IntelGenx earned just from this ac
    complishment should not be
    underestimated, because few companies of IntelGenx’
    s size are able to get drugs all the
    way through the approval process.

    2) By the end of 2013, IntelGenx will have successfull
    y cleared the equivalent of Phase III
    trials in the generic or 505b2 form of 4 branded dr
    ugs that together register annual
    sales of over $4.5billion. (What we don’t know is
    how big a piece of that $4.5billion pie
    will IntelGenx’s marketing partners be able to take
    ...)
    3) IntelGenx has partnered with Par Pharmaceuticals—a
    large and well-respected generic
    drug company—for a generic form of thin-film Suboxo
    ne, a drug which currently sells
    over $1.5billion/year. With Par as a partner, it i
    s reasonable to expect that IntelGenx
    should share in sales somewhere in the $100million-
    $300million range, allowing it to
    generate EPS which should be in the $0.50/share-$1+
    /share range from this drug alone. Less

  • gmger21 by gmger21 Nov 19, 2013 6:01 PM Flag

    Upgrades & Downgrades History
    UPGRADES & DOWNGRADES HISTORY
    Date Research Firm Action From To
    31-Jan-13 Maxim Group Initiated Buy
    11-Sep-12 Brean Murray Initiated Buy
    24-Jun-11 Ladenburg Thalmann Initiated Buy

AGN
166.43+0.83(+0.50%)Jul 11 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Potbelly Corporation
NasdaqGSFri, Jul 11, 2014 4:00 PM EDT
Dean Foods Company
NYSEFri, Jul 11, 2014 4:03 PM EDT